CGRP-monoclonal antibodies in Japan: insights from an online survey of physician members of the Japanese headache societyTsubasa Takizawa, Jin Nakahara, Mamoru Shibata et al.|The Journal of Headache and Pain|2024Cited by 17
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative reviewTsubasa Takizawa, Paolo Martelletti, Keiko Ihara et al.|Expert Opinion on Drug Metabolism & Toxicology|2023Cited by 8
Efficacy and continuability of 675 mg fremanezumab administration over 2 yearsShohei Yoshida, Masahiro Serizawa, Asami Moriya et al.|The Journal of Headache and Pain|2025Cited by 5
Clinical characteristics of 2378 patients presenting with headache disorders to headache clinics in Japan: A clinic-based multicenter studyNoboru Imai, Yasuhiko Matsumori, Tsubasa Takizawa et al.|Clinical Neurology and Neurosurgery|2024Cited by 1
Clinical characteristics of 2,378 patients presenting with headache disorders to headache clinics in Japan: A clinic-based multicenter studyNoboru Imai, Yasuhiko Matsumori, Tsubasa Takizawa et al.|Research Square|2024Cited by 0